October 2007 Fingertip Formulary Insights™
Key Findings
- Medicare limits: Medicare plans had a significantly higher percentage of covered lives with quantity limits across all drug classes (except ED which is generally not a covered class for Medicare).
- Consistency across drug classes: Medicare plans had an average of 61% of covered lives that had quantity limits, compared to 39% for commercial plans. The differences were fairly uniform across all four studied therapeutic areas.
Printable version (PDF 163KB)
Archives
December 2007: Lack of Impact from Two Key Generics in the Anti-depressant Formulary Market
October 2007: Formulary Position Differences between Commercial and Medicare Plans
September 2007: Impact of Patent Loss for Zocor on the Statin Marketplace
- Intro
- Formulary Access
- Trend Analysis
- Prior Authorization
- Quantity Limits
- Step Therapy
- Strategic Implications
Quantity Limits
